Aleksandrs Zhavoronkov, Founder, Chief Executive Officer and Chief Business Officer at Insilico Medicine, shared a post on LinkedIn:
“In the current environment, this is probably the right move for pretty much every pharma company. Cell and gene therapy will be the biggest area in medicine in the next 20-30 years but in the near-term, we are likely to see biologics more than small molecules transition across the board and small molecules for metabolic diseases, CNS and I and I (what I like to call Longevity).
That is why Insilico made a big bet on metabolism, CNS and I and I with a broad portfolio of small molecules. But one day, we may do cell and gene therapy – just need the right time. Let’s analyze the experts who got laid off and help the most competent and hardworking ones find the jobs in startups and early-stage innovative companies that big pharma will later buy.”
More posts on OncoDaily.